This proposal is a request to fund a Clinical Oncology Research Training Program at the Robert H. Lurie Comprehensive Cancer Center at Northwestern University. The program is designed to prepare exceptionally talented clinicians with outstanding research potential for careers in clinical investigation in an academic research environment. Comprehensive training will be provided that emphasizes the interplay of molecular and cell biology, biochemistry and clinical medicine. Trainees will be exposed to state-of-the-art training in original biomedical research pertaining to the Center's four main basic science research areas: 1) Molecular Oncogenesis, 2) Adhesion, Motility and Angiogenesis, 3) Hormone Action and Signal Transduction, and 4) Differentiation and Development. Trainees will have access to high quality laboratory experiences and to clinicians involved in translational research. The laboratory based preceptors of this program are respected scientists with stable NIH funding, significant training experience, and have demonstrated their ability to interact with other members of the Lurie Cancer Center. The clinical mentors are talented investigators who will help the trainee explore the potential applied relevance of their research. A structured educational curriculum and seminar series is designed to complement the trainees laboratory opportunity. It is anticipated our graduates will be among the next generation of clinician scientists capable of taking laboratory discoveries to the clinic with the goal of diminishing human incidence and suffering from cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Institutional National Research Service Award (T32)
Project #
1T32CA079447-01
Application #
2720214
Study Section
Subcommittee G - Education (NCI)
Program Officer
Gorelic, Lester S
Project Start
1999-01-13
Project End
2003-12-31
Budget Start
1999-01-13
Budget End
1999-12-31
Support Year
1
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Northwestern University at Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005436803
City
Chicago
State
IL
Country
United States
Zip Code
60611
Gadd, Samantha; Huff, Vicki; Walz, Amy L et al. (2017) A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor. Nat Genet 49:1487-1494
Ooms, Ariadne H A G; Gadd, Samantha; Gerhard, Daniela S et al. (2016) Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group. Clin Cancer Res 22:5582-5591
Principe, Daniel R; DeCant, Brian; Diaz, Andrew M et al. (2016) PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. Oncotarget 7:28218-34
Ozden, Ozkan; Bishehsari, Faraz; Bauer, Jessica et al. (2016) Expression of an Oncogenic BARD1 Splice Variant Impairs Homologous Recombination and Predicts Response to PARP-1 Inhibitor Therapy in Colon Cancer. Sci Rep 6:26273
Zhou, Zheng; Rademaker, Alfred W; Gordon, Leo I et al. (2016) High Body Mass Index in Elderly Patients With DLBCL Treated With Rituximab-Containing Therapy Compensates for Negative Impact of Male Sex. J Natl Compr Canc Netw 14:1274-1281
Walz, Amy L; Ooms, Ariadne; Gadd, Samantha et al. (2015) Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. Cancer Cell 27:286-97
Zhou, Zheng; Gao, Juehua; Popovic, Relja et al. (2015) Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation. Leuk Lymphoma 56:2895-901
Curi, Dany A; Beauchamp, Elspeth M; Blyth, Gavin T et al. (2015) Pre-clinical evidence of PIM kinase inhibitor activity in BCR-ABL1 unmutated and mutated Philadelphia chromosome-positive (Ph+) leukemias. Oncotarget 6:33206-16
Kumar, Krishan; Raza, Sania S; Knab, Lawrence M et al. (2015) GLI2-dependent c-MYC upregulation mediates resistance of pancreatic cancer cells to the BET bromodomain inhibitor JQ1. Sci Rep 5:9489
Adekola, Kehinde U A; Dalva Aydemir, Sevim; Ma, Shuo et al. (2015) Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin. Leuk Lymphoma 56:450-9

Showing the most recent 10 out of 36 publications